Tuberculosis preventive therapy: An underutilized strategy to reduce individual risk of TB and contribute to TB control

South African Medical Journal

Volumn 104, Issue 5, 2014, Pages 339-343

  Churchyard, G J ^a,b   Chaisson, R E ^c   Maartens, G ^d   Getahun, H ^e  

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE;

BACTERIAL LOAD; DEATH; DRUG MEGADOSE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT TUBERCULOSIS; LIVER TOXICITY; META ANALYSIS (TOPIC); NONHUMAN; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; INCIDENCE; ISONIAZID; RISK REDUCTION BEHAVIOR; SOUTH AFRICA; TUBERCULOSIS;

EID: 84899426406     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.8290     Document Type: Review

References (64)

1. World Health Organization. Global Tuberculosis Report 2013. WHO/HTM/TB/2013. 11. Geneva: WHO, 2012.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-686.[http://dx.doi.org/10.1001/jama.282.7.677]
3. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163(9):1009-1021.[http://dx.doi.org/10.1001/archinte.163.9.1009]
4. Gomez JE, McKinney JD. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004;84(1-2):29-44.[http://dx.doi.org/10.1016/j.tube.2003.08.003]
5. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009;17(5):183-188.[http://dx.doi.org/10.1016/j.tim.2009.02.005]
6. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in highburden townships in South Africa. Int J Tuberc Lung Dis 2010;14(4):406-412.
7. Hanifa Y, Grant AD, Lewis J, Corbett EL, Fielding K, Churchyard G. Prevalence of latent tuberculosis infection among gold miners in South Africa. Int J Tuberc Lung Dis 2009;Jan 13 (1):39-46.
8. Kerkhoff AD, Kranzer K, Samandari T, et al. Systematic review of TST responses in people living with HIV in under-resourced settings: Implications for isoniazid preventive therapy. PLoS One 2012;7(11):e49928.[http:// dx.doi.org/10.1371/journal.pone.0049928]
9. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis - persistence, patience, and winning by waiting. Nat Med 2000;6(12):1327-1329.[http://dx.doi.org/10.1038/82139]
10. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. Lancet 2002;359(9323):2059-2064.[http://dx.doi.org/10.1016/S0140-6736(02)08904-3]
11. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS 2009;4(4):325-333.[http://dx.doi.org/10.1097/COH.0b013e32832c7d61]
12. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010;10(7):489-498.[http://dx.doi.org/10.1016/S1473-3099(10)70078-5]
13. Saraceni V, King BS, Cavalcante SC, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2008;12(7):769-772.
14. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: Implications for programme design. AIDS 2005;19(18):2141-2148.[http://dx.doi.org/10.1097/01.aids.0000194802.89540.e1]
15. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008;22(15):1897-1908.[http://dx.doi.org/10.1097/ QAD.0b013e32830007cd]
16. Bristow CC, Larson E, Vilakazi-Nhlapo AK, Wilson M, Klausner JD. Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa. Int J Tuberc Lung Dis 2012;16(8):1020-1022.[http://dx.doi. org/10.5588/ijtld.11.0744]
17. South African Department of Health. The South African Antiretroviral Treatment Guidelines 2013. http:// www sanac org za/resources/cat_view/1-resources 2014 (accessed 31 March 2014).
18. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. PLoS Med 2011;8 (1):e1000391.[http://dx.doi.org/10.1371/journal.pmed.1000391]
19. Day JH, Charalambous S, Fielding KL, Hayes RJ, Churchyard GJ, Grant AD. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006;10(5):523-529.
20. Lewis JJ, Charalambous S, Day JH, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009;180(12):1271-1278.[http://dx.doi.org/10.1164/ rccm.200806-846OC]
21. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. 2011. http://whqlibdoc who int/ publications/2011/9789241500708_engpdf (accessed 24 March 2014).
22. Rangaka MX, Wilkinson RJ, Glynn JR, et al. Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 2012;55(12):1698-1706.[http://dx.doi.org/10.1093/cid/cis775]
23. Shah M, Ssengooba W, Armstrong D, et al. Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals with suspected tuberculosis in Uganda. AIDS 2014.[Epub ahead of print] [http://dx.doi.org/10.1097/QAD.0000000000000264]
24. Lawn SD, Kerkhof A, Bourton R, et al. Massive diagnostic yield of HIV associated tuberculosis using rapid urine assays in South Africa. Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, MA, USA. Abstract 811LB.
25. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD 000171. Cochrane Database Syst Rev 2010; CD000171.[http://dx.doi.org/10.1002/14651858.CD000171.pub3]
26. Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: A novel randomized incremental recruitment study. JAMA 2005;293(22):2719-2725.[http://dx.doi.org/10.1001/jama.293.22.2719]
27. Churchyard GJ, Scano F, Grant AD, Chaisson RE. Tuberculosis preventive therapy in the era of HIV infection: Overview and research priorities. J Infect Dis 2007;196(Suppl 1):S52-S62.[http://dx.doi.org/10.1086/518662]
28. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIVinfected adults in South Africa: A prospective cohort. AIDS 2009;23(5):631-636.[http://dx.doi.org/10.1097/ QAD.0b013e328327964f]
29. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007;21(11):1441-1448.[http://dx.doi.org/10.1097/QAD.0b013e328216f441]
30. Charalambous S, Grant AD, Innes C, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24(Suppl 5):S5-S13.[http://dx.doi.org/10.1097/01.aids.0000391010.02774.6f]
31. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial. Lancet 2011;377(9777):1588-1598.
32. Rangaka MX, Boulle A, Wilkinson RJ, et al. Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. 19th International AIDS Conference, 22-27 July 2012, Washington, DC, USA. Abstract THLBB03.
33. Rangaka MX, Wilkinson R, Wilkinson K, et al. Effect of tuberculin skin testing or interferon-release on the benefit of concurrent isoniazid preventive therapy with ART: Subgroup analysis of a randomized controlled trial. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, GA, USA. Poster abstract 189LB.
34. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365(1):11-20.[http://dx.doi.org/10.1056/NEJMoa1005136]
35. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis 1967;95(6):935-943.[http://dx.doi.org/10.1056/NEJMoa1005136]
36. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: A final report of the Bethel isoniazid studies. Am Rev Respir Dis 1979;119(5):827-830.
37. Ferebee SH, Hopwood L, Palmer CE. Studies on prevention of experimental tuberculosis with isoniazid. II. Effects of different dosage regimens. Am Rev Tuberc 1956;74(6):917-939.
38. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental instutions. Am Rev Respir Dis 1963;88:161-175.
39. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15(16):2137-2147.[http://dx.doi.org/10.1097/00002030-200111090-00009]
40. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15(2):215-222.[http://dx.doi.org/10.1097/00002030-200101260- 00011]
41. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997;337(12):801-808.[http://dx.doi.org/10.1056/NEJM199709183371201]
42. Samandari T, Agizew T, Tedla Z, et al. TB incidence increase after cessation of 36 months isoniazid prophylaxis in HIV+ adults in Botswana. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, WA, USA. Abstract 147.
43. Churchyard GJ, Fielding KL, Lewis JJ, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med 2014;370(4):301-310.[http://dx.doi.org/10.1056/NEJMoa1214289]
44. Grant AD, Mngadi KT, van Halsema CL, Luttig MM, Fielding KL, Churchyard GJ. Adverse events with isoniazid preventive therapy: Experience from a large trial. AIDS 2010;24(Suppl 5):S29-S36.[http://dx.doi. org/10.1097/01.aids.0000391019.10661.66]
45. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12(5):744-751.[http://dx.doi.org/10.3201/eid1205.050681]
46. van Halsema CL, Fielding KL, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010;24(7):1051-1055.[http:// dx.doi.org/10.1097/QAD.0b013e32833849df]
47. Mills HL, Cohen T, Colijn C. Response to comment on 'Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: A model-based analysis'. Sci Transl Med 2013;5 (204): 204lr4.
48. Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: A model-based analysis. Sci Transl Med 2013;5(180):180ra49.
49. Horwitz O, Payne PG, Wilbek E. Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland. Bull World Health Organ 1966;35(4):509-526.
50. Nyboe J, Farah AR, Christensen OW. Report on tuberculosis chemotherapy pilot project (Tunisia 9). WHO/ TB/Technical Information/10. 22 April 1963.
51. Chihota VN, Popane F, Churchyard GJ, et al. Community-wide isoniazid preventive therapy among gold miners in South Africa: The Thibela TB study. South African TB Conference 2012, 12-15 June 2012, Durban, South Africa. http://www.auruminstitute.org/thibela-TB/Thibela-SA-TB-conf-12-06-12.pdf (accessed 11 April 2014).
52. Wakamoto Y, Dhar N, Chait R, et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science 2013;339(6115):91-95.[http://dx.doi.org/10.1126/science.1229858]
53. Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171(12):1430-1435.[http://dx.doi.org/10.1164/ rccm.200409-1200OC]
54. Charalambous S, Grant AD, Moloi V, et al. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2008;12(8):942-948.
55. Miyazaki E, Chaisson RE, Bishai WR. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. Antimicrob Agents Chemother 1999;43(9):2126-2130.
56. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. Am J Respir Crit Care Med 1994;150(5 Part 1):1355-1362.[http://dx.doi.org/10.1164/ajrccm.150.5.7952564]
57. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365(23):2155-2166.[http://dx.doi.org/10.1056/NEJMoa1104875]
58. Sterling TR, Person AK. TB Trials Consortium Study 26.AIDS Clinical Trials Group 5259. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection. The PREVENT TB Study. 19th International AIDS Conference, 22-27 July 2012, Washington, DC, USA. Abstract MOAB0302.
59. Sterling T, Benson C, Scott N, et al. Three months of weekly rifapentine+INH for M. tuberculosis infection in HIV-infected persons. Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, MA, USA. Abstract 817.
60. World Health Organization. The Stop TB Strategy: Building on and enhancing DOTS to meet the TB-related Millenium Development Goals. http://whqlibdoc whoint/hq/2006/WHO_HTM_STB_2006368_engpdf (accessed 24 March 2014).
61. World Health Organization. WHO policy on collaborative TB/HIV activities: Guidelines for national programmes and other stakeholders. http://www whoint/tb/publications/2012/tb_hiv_ policy_9789241503006/en/indexhtml (accessed 24 March 2014).
62. Suthar AB, Lawn SD, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: A systematic review and meta-analysis. PLoS Med 2012;9 (7):e1001270.[http://dx.doi.org/10.1371/journal. pmed.1001270]
63. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013;34(7):271-286.[http://dx.doi.org/10.1146/annurev-publhealth-031912-114431]
64. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009;106(33):13980-13985.[http://dx.doi. org/10.1073/pnas.0901720106]